The Patient Role in Stimulating Chronic Fatigue Syndrome Drug Development
This article was originally published in RPM Report
Executive Summary
The Food & Drug Administration convened a two-day meeting with CFS patients, advocates, clinicians and researchers in late April. One of the speakers invited by FDA was former Lilly corporate strategy exec Bernard Munos. His presentation was part exhortation, part reality check – delivering in straightforward, practical terms how patient groups can step into the drug development process to deliver data for regulators and commercial developers. Here is a transcript of his remarks, lightly edited for clarity.
You may also be interested in...
Patient Feedback Pioneers: Chronic Fatigue Advocates Prepare for First PDUFA V Meeting
FDA has selected CFS/ME as the first topic for the PDUFA V patient-centered drug development initiative. The lessons learned from this session will inform future work on patient engagement in drug development both for FDA—and for patient advocates.
FDA’s Draft Agenda for the CFS/ME Patient Input Meeting
Here is a draft agenda made available by FDA ahead of the April 25-26 first-ever PDUFA V patient input workshop on chronic fatigue syndrome/myalgic encephalomyelitis. FDA notes that a final agenda will be made available a week before the meeting.
How Not To Develop A Drug
What is the best way to encourage drug development in an unmet medical need? Chronic Fatigue Syndrome advocates argue that FDA should approve a drug—specifically Ampligen—even if it falls far short of reaching typical standards of evidence. FDA disagrees, and gained the backing of its advisory committee on that point. But the vote was close…